AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B

JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.

alt

Read more:

AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B

ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the infection, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.

alt

Read more:

AASLD 2017: Women with Fatty Liver Disease at Higher Risk for Heart Disease

Women with non-alcoholic fatty liver disease (NAFLD) had a higher risk of cardiovascular events including chest pain and heart failure compared to women without the condition -- and about the same risk as men with NAFLD -- in a study presented at the 2017 AASLD Liver Meeting in October in Washington, DC.

alt

Read more:

AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B

Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.

alt

Read more:

AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study

Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.

alt

Read more: